Helix BioPharma Corp. and Moffitt Cancer Center extend collaboration on immunotherapy, including study of L-DOS47 with PD-1/PD-L1 inhibitors

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has extended its collaboration agreement with Moffitt Cancer Center for an additional year.

20181010-HBP-Press-Release-Moffitt-Collaboration-L-DOS47-Immunotherapy-FINAL.pdf